Filters

ADAR1 Antibody, Cy7 Conjugated

ADAR1 Antibody, Cy7 Conjugated size: 0.1ml 350

Price 350
Size 0.1ml
Long name Cy7 Conjugated, ADAR1 Polyclonal Antibody
CategoryConjugated Primary Antibodies
ConjugationCy7
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenADAR1
SpecificityThis is a highly specific antibody against ADAR1
ModificationUnmodified
Modification siteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
Immunogen_range150-200/1226
Subcellular location Nucleus, Cytoplasm
SourceKLH conjugated synthetic peptide derived from human ADAR1
Gene ID number103
Swiss ProtP55265
Tested applicationsIF(IHC-P)
Recommended dilutionsIF(IHC-P)(1:50-200)
CrossreactivityHuman
Crossreactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Antigen background Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing), Enhances the replication of MV, Exhibits either a proviral (HDV, Exhibits low-level editing at the GRIA2 Q/R site, Impairs HCV replication via RNA editing at multiple sites, Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), Its viral RNA substrates include: hepatitis C virus (HCV), MV, RNA stability by changing sequences involved in nuclease recognition, Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities, Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence, This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions, and human immunodeficiency virus type 1 (HIV-1), but edits efficiently at the R/G site and HOTSPOT1, editing-independent (VSV and MV) or both (HIV-1), genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, hepatitis delta virus (HDV), measles virus (MV), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3), pre-mRNA splicing by altering splice site recognition sequences, vesicular stomatitis virus (VSV), Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA
Excitation Emission743nm/767nm
Synonyms ADAR1
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°
ConjugatedThese antibodies are excite for emission at 650 nm and detected at a 676 nm wavelengths
Gene targetADAR1 Conjugated
Short name Conjugated, ADAR1 Antibody
Technique antibodies against human proteins, antibodies for, antibody Conjugates, Antibody
LabelCy7
Alternative name cyanine 7 coupled, ADAR1 (Antibody to)
Alternative techniqueantibodies
Identity 225
Gene ADAR
Long gene name RNA specific , adenosine deaminase
Synonyms gene IFI4 G1P1
Synonyms gene name interferon-induced protein 4
Locus 1q21, 3
Discovery year 1995-12-12
GenBank acession BC038227
Entrez gene record 103
Pubmed identfication 7972084
RefSeq identity NM_001111
Classification Adenosine deaminases acting on RNA
Havana BLAST/BLAT OTTHUMG00000037261

Subscribe to our Newsletter